Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT06738563
Recruiting Observational

Impact of Breast Milk on the Infectivity and Transmission of Different Viruses "BREASTMILKVIR"

NCT06738563 · tracked via the Priya Life Science France tracker
Sponsor
Institut Pasteur
Phase
Observational
Started
2025-09-10
Last updated
2025-12-15

Condition(s) studied

Breastmilk Collection

Investigational drug(s) / intervention(s)

Collection breast milk

Collection breast milk: Collection of a milk sample taken as part of women's donation

Study summary

Exclusive breastfeeding during the first six months of life and continued breastfeeding for at least 24 months constitute the optimal feeding method for infants and young children.

However, breast milk and breastfeeding can be significant pathways for the transmission of certain viruses.

The objective of this study is to examine the influence of human breast milk and its composition on viral infectivity and viral transmission of the HTLV-1 virus and arboviruses such as Zika virus, yellow fever, dengue, and tick-borne encephalitis.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Age \> 18 years * Female gender * Lactarium Ile-de-France donors * Subjects covered by a Social Security scheme, excluding State Medical Aid No inclusion criteria: \- Women opposing participation in the study Exclusion Criteria: \- Positive HIV, HBV, HCV and HTLV serologies (Lactarium exclusion criteria)

Primary outcome measure(s)

  • Study the influence of breast milk and its composition on viral infectivity and oral transmission of HTLV-1 and arboviruses such as Zika virus, yellow fever virus, dengue virus, and tick-borne encephalitis virus. — 36 months
    Various viruses will be incubated with milk samples. The influence of milk on the different viruses will be studied. The capacity of these viruses incubated with milk to infect the target cells (immune or epithelial cells, depending on the virus) will be measured (measurement of the number of infected cells).

Trial sites (1)

FacilityCityRegionStatus
Lactarium Ile-de-France, Necker-Enfents Malades Hospital Paris France Recruiting

More Institut Pasteur trials in France

Development of a Battery of Audiological Tests for the Precision Diagnosis of Age-related Hearing Loss Recruiting
The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis Recruiting
Study of Auditory Perception After Progressive Exposure to Aversive Sounds in People With Misophonia Starting soon
A Trial to Evaluate the Safety, Immunogenicity and the Optimal Dose of MOPEVAC-Las Vaccine Candidate Against Lassa Fever Recruiting
Description of the Immune Response to Yellow Fever Vaccination Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06738563 on ClinicalTrials.gov ↗ ← All trials in France